Summary

In a prespecified analysis of the TRITON-TIMI 38 trial, prasugrel was more effective and as safe as standard dose clopidogrel in patients with ST-elevation myocardial infarction (STEMI) who were undergoing planned percutaneous coronary intervention. This article presents an important analysis of patients with STEMI, a stratified group of patients at the time of randomization in the TRITON-TIMI 38 clinical trial.